DrugPatentWatch Database Preview
Intercept Pharms Inc Company Profile
What is the competitive landscape for INTERCEPT PHARMS INC, and when can generic versions of INTERCEPT PHARMS INC drugs launch?
There are four US patents protecting INTERCEPT PHARMS INC drugs.
There are forty-three patent family members on INTERCEPT PHARMS INC drugs in twenty-four countries and six supplementary protection certificates in five countries.
Summary for Intercept Pharms Inc
| International Patents: | 43 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Intercept Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 8,377,916 | ➤ Sign Up | ➤ Sign Up | ||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 9,238,673 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Intercept Pharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,786,102 | Steroids as agonists for FXR | ➤ Sign Up |
| 9,732,116 | Preparation and uses of obeticholic acid | ➤ Sign Up |
| 9,732,117 | Steroids as agonists for FXR | ➤ Sign Up |
| 8,969,330 | Steroids as agonists for FXR | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Intercept Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Denmark | 1392714 | ➤ Sign Up |
| Brazil | 112014031828 | ➤ Sign Up |
| India | 2561MUN2014 | ➤ Sign Up |
| Australia | 2016200832 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Intercept Pharms Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90020-0 | Sweden | ➤ Sign Up | PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215 |
| /2017 | Austria | ➤ Sign Up | PRODUCT NAME: OBETICHOLSAEURE, DESSEN PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE ODER AMINOSAEURE-KONJUGATE; REGISTRATION NO/DATE: EU/1/16/1139 20161212 |
| 2017 00025 | Denmark | ➤ Sign Up | PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215 |
| 2017000034 | Germany | ➤ Sign Up | PRODUCT NAME: OBETICHOLSAEURE (OBETICHOLIC ACID); REGISTRATION NO/DATE: EU/1/16/1139 20161212 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
